SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-024824
Filing Date
2021-02-17
Accepted
2021-02-17 16:13:09
Documents
16
Period of Report
2021-02-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm216892d1_8k.htm   iXBRL 8-K 29755
2 EXHIBIT 1.1 tm216892d1_ex1-1.htm EX-1.1 168702
3 EXHIBIT 5.1 tm216892d1_ex5-1.htm EX-5.1 14078
7 GRAPHIC tm216892d1_ex5-1img01.jpg GRAPHIC 4159
8 GRAPHIC tm216892d1_ex5-1img02.jpg GRAPHIC 4159
  Complete submission text file 0001104659-21-024824.txt   448200

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA crvs-20210212.xsd EX-101.SCH 3199
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE crvs-20210212_lab.xml EX-101.LAB 34592
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE crvs-20210212_pre.xml EX-101.PRE 22719
9 EXTRACTED XBRL INSTANCE DOCUMENT tm216892d1_8k_htm.xml XML 3723
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 21644876
SIC: 2834 Pharmaceutical Preparations